#AUA2024 Dr Steinmetz Alexis Steinmetz Advancing our understanding of the role of nadofarogene therapy and the immune tumor micro environment in murine mouse model

Equitable trial enrollment is critical to improving bladder cancer outcomes. When examining sex based disparities in urothelial carcinoma, we need to consider incidence differences between UTUC (~40% female) and Bladder cancer (~24% female)

First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with #NMIBC with select FGFR alterations. Presentation by Antoni Vilaseca, MD, FEBU. #AUA24 written coverage by Julian Chavarriaga University of Toronto > bit.ly/3wzAACy Amer. Urol. Assn.

What happens when Michigan Urology researchers interested in SDOH, cancer disparities, and clinical trials hang out? Lindsey Herrel Kristian Stensland, MD MPH U-M IHPI Nat’l Clinician Scholars Program at U-M IHPI We looked at the geographic distribution of clinical trial opportunities across the US in context of social vulnerability.

#SunRISe-3 trial: TAR-200 with or without cetrelimab vs BCG for BCG-naive HR #NMIBC. Sam S. Chang MD, MBA Vanderbilt Urology and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center discuss insights from this trial which could shift treatment paradigms, offering a promising alternative to BCG > bit.ly/44A2gUA

Glad to present our work on physician reported 1L tx patterns 5 European countries. ASCO #ASCO24 Enrique Grande Tom Powles 👉 >75% pts offered systemic 1L tx 👉advanced age (> med 74 yr) was a major criteria for not offering Tx Cleveland Clinic MD meetings.asco.org/abstracts-pres…

⬇️📍V. proud of Mohammad Jad Moussa, MD, MSc presenting small cell bladder cancer relapse factors with aim to cure⬆️pts. #asco24 ✔️any residual small cell regardless of path stage after NAC ⬆️relapse ✔️ small cell clones drive majority of relapses (more to come) ✔️ cT, pN+ as expected ⬆️relapse

This....unless patient reported outcomes and toxicity is presented, avoid terms like manageable toxicities. Report #PROS

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by Amanda Myers

If this was a report on drug X for BCG unresponsive disease, what would you think? CR 3mos 75% CR 24mos 55% Our report challenges assumptions of disease course and response. Single-arm trials lack external validity. With multiple approved agents, it's time for randomized trials!

It's encouraging to see the lively discussion this has sparked. To clarify: we are not advocating for rescue BCG for all BCGU patients. What we are emphasizing is that if BCG were evaluated today in a single-arm registration study, it could likely be ‘approved’. While we must

Finally released! Huge kudos to Laura S. Mertens, Max Bruins and the #EAU NMIBC and MIBC guidelines panel for creating a practical follow-up framework for #bladdercancer patients after RC Link ➡️ authors.elsevier.com/c/1jIOc_wtO--z… European Association of Urology (EAU) European Urology Oncology

When to stop PSA screening and how to say it. Very insightful talk from Scott Eggener at #CUA24

#Readability of patient education materials in uro-oncology 📉 Most materials fail to meet readability standards 📊 Mean FRES scores: EAU 50.9, AUA 64.0 (it should be 80!!) 📑 Only 18.6% met readability criteria We need to do more; we must do better for our #patients!

Patient burdens and openness to in-home intravesical therapy for #BladderCancer - Timothy Lyon, MD Mayo Clinic & Amanda Myers MD Anderson Cancer Center join Sam S. Chang MD, MBA to discuss insights from their study on the patient-reported treatment burdens > bit.ly/4dzBW0m

What an incredible evening with #IBCG24 colleagues, celebrating a day of hard work! Special thank you to IBCG board for flawless execution .. time to recharge for another busy 😴 Janet Kukreja Petros Grivas Roger Li Dr. Bishoy M. Faltas Amanda Myers Kelly Bree Bogdana Schmidt MD, MPH

#IBCG24 Retreat, the IBCG continues to lead the way in addressing global educational needs and learning gaps in order to improve care for people affected by #bladdercancer around the 🌎 All through proactive and dedicated global collaboration. A big thank you to

Bowling for Bladder Cancer 🇺🇸 🇨🇦 🇬🇧 🇮🇹 🇳🇱 🇩🇪 🇦🇺 🇮🇳 🇲🇦 🇬🇷 🇨🇱 #IBCG24 IBCG #BladderCancer

Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG) sciencedirect.com/science/articl… European Urology Oncology IBCG